STOCK TITAN

TAK Files Form 144 for Minor Insider Sale of 4.5K ADSs

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
144

Rhea-AI Filing Summary

Takeda Pharmaceutical Company Limited (TAK) has filed a Form 144 indicating a proposed sale of restricted securities.

  • Securities to be sold: 4,477 American Depositary Shares (ADSs).
  • Estimated market value: US $69,035.34.
  • Broker: Interactive Brokers LLC, Greenwich, CT.
  • Approximate sale date: 9 July 2025 on the NYSE.
  • Shares outstanding: 123,490,548 ADSs – the planned sale represents less than 0.01% of this total.
  • Source of shares: Vested Restricted Stock Unit (RSU) awards acquired 1 July 2025 as compensation from Takeda Pharmaceutical Company Limited.
  • Prior sales: None reported in the past three months.

The filing is routine and does not include earnings data or announce any strategic transactions. It simply registers a modest insider sale that is immaterial relative to the company’s share base.

Positive

  • None.

Negative

  • None.

Insights

TL;DR: Small insider Form 144 for 4,477 ADSs (US$69k) is routine and immaterial; no strategic signal for TAK investors.

The notice covers a proposed sale amounting to roughly 0.004% of Takeda’s ADS float. Such filings are common for employees or executives monetising vested RSUs. The aggregate value is negligible for a US$50 billion-plus market-cap company and does not alter supply–demand dynamics. No adverse information is asserted in the certification, and no additional sales have occurred in the prior quarter. I view the disclosure as non-impactful to the investment thesis or valuation.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

FAQ

How many Takeda (TAK) ADSs are being sold under this Form 144?

The filing covers 4,477 ADSs.

What is the approximate market value of the proposed TAK share sale?

The aggregate market value is US$69,035.34.

When is the expected sale date for the Takeda ADSs?

The filer plans to sell on or about 9 July 2025.

What percentage of Takeda’s outstanding ADSs does this sale represent?

Less than 0.01% of the 123,490,548 ADSs outstanding.

Where will the TAK ADSs be sold and through which broker?

They are slated for sale on the NYSE via Interactive Brokers LLC.
Takeda Pharm

NYSE:TAK

TAK Rankings

TAK Latest News

TAK Latest SEC Filings

TAK Stock Data

54.24B
3.16B
0.01%
2.51%
0.24%
Drug Manufacturers - Specialty & Generic
Healthcare
Link
Japan
Tokyo